stockrowRoyalty Pharma PLC
RPRX Healthcare Biotechnology
Royalty Pharma PLC’s revenue for fiscal 2025 (year ended December 2025) was $2.4 billion, up 5.06% from fiscal 2024.
- Revenue
- +13.3%
- EPS
- −51.5%
- Free cash flow
- +364.6%
- Total debt
- −4.00%
Quarter to September 2026, against a year earlier
Follow RPRX
Alert me
Royalty Pharma PLC (RPRX) Total debt
Royalty Pharma PLC's total debt at the end of fiscal 2025 was $9.0B, up 17.6% from $7.6B in fiscal 2024. At the end of the quarter to 30 September 2026 it was $8.6B. Over the past ten years it has ranged from $5.8B (fiscal 2020) to $9.0B (fiscal 2025) — the current reading is the highest in ten years. Royalty Pharma PLC ranks 1st of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $9.0B | 17.58% |
| FY2024 | $7.6B | 24.08% |
| FY2023 | $6.1B | (13.79%) |
| FY2022 | $7.1B | 0.29% |
| FY2021 | $7.1B | 22.00% |
| FY2020 | $5.8B | (7.18%) |
| FY2019 | $6.3B | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $8.6B | (4.18%) |
| Jun 2026 | $9.0B | 0.06% |
| Mar 2026 | $9.0B | 0.06% |
| Dec 2025 | $9.0B | 0.06% |
| 23 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| RPRX Royalty Pharma PLC | $8.6B |
| GMAB Genmab A/S Sponsored ADR compare | $5.1B |
| RVMD Revolution Medicines, Inc. compare | $1.0B |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $825.2M |
| INSM Insmed, Inc. compare | $562.8M |
| BNTX BioNTech SE Sponsored ADR compare | $414.1M |
| ROIV Roivant Sciences Ltd. compare | $323.7M |
| INCY Incyte Corporation compare | $27.6M |
| ARGX argenex SE compare | $7.6M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on RPRX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement